Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement
Tania Rodriguez-Gabella, Pablo Catalá, Antonio J Muñoz-García, Luis Nombela-Franco, Raquel Del Valle, Enrique Gutiérrez, Ander Regueiro, Victor A Jimenez-Diaz, Henrique B Ribeiro, Fernando Rivero, Jose Antonio Fernandez-Diaz, Philippe Pibarot, Juan H Alonso-Briales, Gabriela Tirado-Conte, César Moris, Felipe Diez Del Hoyo, Gustavo Jiménez-Britez, Nicolas Zaderenko, Fernando Alfonso, Itziar Gómez, Manuel Carrasco-Moraleja, Josep Rodés-Cabau, J Alberto San Román Calvar, Ignacio J Amat-Santos, Tania Rodriguez-Gabella, Pablo Catalá, Antonio J Muñoz-García, Luis Nombela-Franco, Raquel Del Valle, Enrique Gutiérrez, Ander Regueiro, Victor A Jimenez-Diaz, Henrique B Ribeiro, Fernando Rivero, Jose Antonio Fernandez-Diaz, Philippe Pibarot, Juan H Alonso-Briales, Gabriela Tirado-Conte, César Moris, Felipe Diez Del Hoyo, Gustavo Jiménez-Britez, Nicolas Zaderenko, Fernando Alfonso, Itziar Gómez, Manuel Carrasco-Moraleja, Josep Rodés-Cabau, J Alberto San Román Calvar, Ignacio J Amat-Santos
Abstract
Background: Several studies have demonstrated the benefits of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, but the presence of persistent fibrosis and myocardial hypertrophy has been related to worse prognosis.
Objectives: The aim of this study was to explore the potential benefits of renin-angiotensin system (RAS) inhibitors on left ventricular remodeling and major clinical outcomes following successful transcatheter aortic valve replacement (TAVR).
Methods: Patients from 10 institutions with severe aortic stenosis who underwent TAVR between August 2007 and August 2017 were included. All baseline data were prospectively recorded, and pre-specified follow-up was performed. Doses and types of RAS inhibitors at discharge were recorded, and matched comparison according to their prescription at discharge was performed.
Results: A total of 2,785 patients were included. Patients treated with RAS inhibitors (n = 1,622) presented similar surgical risk scores but a higher rate of all cardiovascular risk factors, coronary disease, and myocardial infarction. After adjustment for these baseline differences, reduction of left ventricular volumes and hypertrophy was greater and cardiovascular mortality at 3-year follow-up was lower (odds ratio: 0.59; 95% confidence interval: 0.41 to 0.87; p = 0.007) in patients treated with RAS inhibitors. Moreover, RAS inhibitors demonstrated a global cardiovascular protective effect with significantly lower rates of new-onset atrial fibrillation, cerebrovascular events, and readmissions.
Conclusions: Post-TAVR RAS inhibitors are associated with lower cardiac mortality at 3-year follow-up and offer a global cardiovascular protective effect that might be partially explained by a positive left ventricular remodeling. An ongoing randomized trial will help confirm these hypothesis-generating findings. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).
Keywords: RAS inhibitors; TAVR; fibrosis; hypertrophy.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed